Advertisements


Divi"s stock: Pricing pressure for drug makers can lead to more outsourcing

Analysts at Motilal Oswal Securities expect Divi's earnings before interest, tax, depreciation and amortisation (Ebitda) margin to improve by 400 basis points to 36 per cent.....»»

Category: topSource: business-standardApr 16th, 2018

Generic drug makers under pressure following Aceto, Novartis news

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 19th, 2018

Brainstorm Health: Most Innovative Drug Makers, Israel’s Health Data Push, Shire Stock Soars

Brainstorm Health Daily: March 28, 2018 Hello and happy hump day, readers! This is Sy. W.....»»

Category: europeSource: fortuneMar 28th, 2018

Here"s Why You Should Hold Digital Realty (DLR) Stock Now

Digital Realty Trust (DLR) enjoys a solid operating platform and a healthy balance sheet. However, aggressive pricing pressure is likely to continue in the upcoming period amid severe competi.....»»

Category: smallbizSource: nytMar 26th, 2018

Analyst: FDA Letter Could Lead To 1-Year Delay For Celgene"s Ozanimod

Celgene Corporation (NASDAQ: CELG) is under continued stock pressure Wednesday after the U.S. Latest Ratings for .....»»

Category: blogSource: benzingaFeb 28th, 2018

Aradigm"s stock plunges to lead Nasdaq losers after Linhaliq"s NDA fails to get approved

Shares of Aradigm Corp. plunged 21% toward a four-month low, after the drug maker said the Food and Drug Administration informed that company that its new drug application (NDA) for its lung infection treatment could not be approved in its current for.....»»

Category: topSource: marketwatchJan 29th, 2018

Market Snapshot: Stocks struggle to remain in record territory as tech shares come under pressure

U.S. stock benchmarks on Wednesday trade in record territory as bank stocks lead the way, extending a solid start to the year for Wall Street equities on the back of better-than-expected earnings......»»

Category: topSource: marketwatchJan 24th, 2018

After A Freefall In Axovant Shares, Chardan Upgrades

Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value Lates.....»»

Category: blogSource: benzingaJan 10th, 2018

DelMar Pharmaceuticals" stock rockets after cancer treatment granted "Fast Track" designation

Shares of DelMar Pharmaceuticals Inc. rocketed 40% in premarket trade Tuesday, after the biopharmaceutical company said its lead-product cancer treatment, VAL-083, was granted "Fast Track" designation by the Food and Drug Administration. "Fa.....»»

Category: topSource: marketwatchDec 26th, 2017

First-tier China solar mono-Si wafer makers under pricing pressure

First-tier China-based solar mono-Si wafer makers have been under pressure from clients seeking lower prices but they are striving to maintain their quotes, according to industry sources......»»

Category: topSource: digitimesDec 25th, 2017

La Jolla stock jumps 16% after FDA approval

La Jolla Pharmaceutical Co. rose more than 16% Thursday afternoon after the company announced it had received approval for a new drug to increase blood pressure. The drug, Giapreza, is used to treat .....»»

Category: topSource: marketwatchDec 21st, 2017

Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa

Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in pat.....»»

Category: dealsSource: nytDec 19th, 2017

NMDC: Pricing outlook signals more gains

Rising volumes, realisations can lead to strong stock returns.....»»

Category: topSource: business-standardDec 18th, 2017

Competition clouds Cadila Healthcare"s FY19 profit

Approval to Teva for key drug Lialda and sustained price erosion lead to stock downgrades.....»»

Category: topSource: business-standardNov 12th, 2017

Will Mylan Crush Teva’s Generic Dreams?

Bad news may be baked into shares of drug makers Mylan and Teva even as a new generic poses a pricing challenge......»»

Category: blogSource: barronsNov 6th, 2017

US FDA lifts import alert on Divi"s Lab Vizag unit in record seven months

This is seen as unprecedented for Indian drug makers.....»»

Category: topSource: business-standardNov 2nd, 2017

After Gaining 16% Early Last Week, This Marijuana Stock Quickly Kissed It All Goodbye

Recurring issues with its lead drug sent this pot stock into a late-week tailspin......»»

Category: topSource: foxnewsOct 11th, 2017

Soon, drug makers will have to declare medicine cost price, MRP on labels

Pharma companies feat the move might hit their pricing strategies and put local firms in a disadvantageous position.....»»

Category: topSource: business-standardOct 10th, 2017

Main Line biopharm firm completes $40.3M stock sale

The proceeds will be used to fund further clinical testing of the company's lead new drug candidate......»»

Category: topSource: bizjournalsSep 21st, 2017

Pfizer"s stock jumps to 13-month high to lead Dow gainers after analyst upgrade

Shares of Pfizer Inc. surged 1.3% in morning trade Wednesday toward a 13-month high, after the drug maker was upgraded at Morgan Stanley, which cited valuation following "a long period of middling p.....»»

Category: topSource: marketwatchSep 20th, 2017

Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?

Sage's lead drug candidate whiffs in a late-stage study......»»

Category: topSource: foxnewsSep 12th, 2017